Healthcare / BiotechnologyKOSDAQ
$1791.00
-75.00 (-4.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-32.4B · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$111.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.5%
↓Gross Margin
35.4%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-29.5%
FCF CAGR
—
FCF margin
-3803.8%
FCF / Net income
1.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $880.1M · net income $-29.06B · FCF $-33.48B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $880.1M | $880.1M | $759.7M | $1.27B | $2.51B |
| Net Income | $-29.06B | $-29.06B | $-43.38B | $-29.21B | $-19.93B |
| EBITDA | $-24.77B | $-24.77B | $-39.60B | $-26.58B | $-18.72B |
| EPS | -434.00 | -434.00 | -407.48 | -713.79 | -496.00 |
| Gross Margin | 35.4% | 35.4% | 29.3% | 1.2% | 28.7% |
| Operating Margin | -2201.0% | -2201.0% | -4484.2% | -2445.4% | -1004.1% |
| Net Margin | -3302.2% | -3302.2% | -5710.5% | -2292.3% | -794.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.61 | 1.51 | 0.32 |
| Current Ratio | 3.37 | 3.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-33.48B | $-33.48B | $-28.86B | $-32.36B | $-20.52B |
| Returns | |||||
| ROE | -42.5% | -42.5% | -154.2% | -292.7% | -132.0% |
| Valuation | |||||
| P/B | 1.63 | 1.63 | 6.13 | 14.39 | 8.42 |
| Growth & Yield | |||||
| Revenue Growth | 15.9% | 15.9% | -40.4% | -49.2% | — |
| EPS Growth | -6.5% | -6.5% | 42.9% | -43.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-407.48 → -434.00
Residual
-34.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.